Catalyst Brief

← Calendar

Readoutin 14d

AbbVie — ABBV-RGX-314

Phase 3 primary completion: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD.

Date
Dec 2026
Type
Readout
Indication
AMD

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from AbbVie

  1. Apr2027
  2. Mar2027
    Readoutin 104d
    AbbVie — Upadacitinib
    Phase 3 primary completion: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus.
  3. Mar2027
    Readoutin 104d
    AbbVie — Risankizumab SC
    Phase 3 primary completion: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease..
  4. Dec2026
    Readoutin 14d
    AbbVie — Lutikizumab
    Phase 3 primary completion: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa.